Healthcare Services

Cancer Cachexia Industry Expansion Forecast Showing Market Size of $3.35 Billion by 2030 at 5.1% CAGR

March 30, 2026March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Cancer Cachexia Market Expected To Change Between 2026 And 2030?

The cancer cachexia market size has shown robust expansion in recent years. It is expected to rise from $2.6 billion in 2025 to $2.75 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. The expansion observed historically is due to factors like an increasing occurrence of late-stage cancer diagnoses, greater clinical understanding of cachexia management, expanding hospital pharmacy distribution networks, the early acceptance of anabolic agents, and the widespread development of supportive oncology care.

The cancer cachexia market is anticipated to experience robust expansion over the coming years. It is projected to reach $3.35 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.1%. This growth during the forecast period is attributable to the increasing need for personalized cachexia treatments, a surge in clinical research investigating novel mechanisms, the broadening of outpatient oncology services, the rising adoption of digital patient monitoring instruments, and an elevated focus on quality-of-life outcomes. Significant trends expected in this period encompass the greater utilization of combination drug regimens, an intensified focus on muscle preservation therapies, the wider embrace of nutritional supplementation strategies, the expansion of anti-inflammatory cachexia treatments, and more effective monitoring of cachexia progression.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

Which Major Factors Are Driving The Expansion Of The Cancer Cachexia Market?

The rising incidence of cancer is anticipated to stimulate expansion within the cancer cachexia market moving forward. Cancer is defined as a disease where abnormal cells multiply unchecked within the body, forming masses and impairing normal bodily functions. The increase in cancer cases can be attributed to several elements, including shifts in lifestyle, environmental influences, an aging population, genetic predispositions, enhanced diagnostic techniques enabling earlier detection, and increased public consciousness prompting more individuals to seek medical attention. Advances in medical technology and a more comprehensive understanding of cancer and its associated complications are leading to a higher frequency of cancer cachexia diagnoses and reporting. Healthcare professionals are enhancing their capability to identify cachexia symptoms, thereby facilitating earlier interventions and the initiation of treatment. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which translates to over 450 cases each day, with males constituting approximately 55% of these diagnoses. Therefore, the increasing prevalence of cancer is a key driver for the growth of the cancer cachexia market.

How Is The Cancer Cachexia Market Structured Across Different Segments?

The cancer cachexia market covered in this report is segmented –

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate, Medroxyprogesterone Acetate

2) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids, Progestogens + Anabolic Agents, Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents, Appetite Stimulants, Anti-inflammatory Drugs

Which Trends Are Shaping The Future Of The Cancer Cachexia Market?

Leading companies operating within the cancer cachexia market are developing innovative medications, such as monoclonal antibodies for cachexia, with the goal of creating a targeted treatment for cancer cachexia, intended to improve body weight, muscle mass, and the overall quality of life for affected patients. A monoclonal antibody for cachexia works by targeting and inhibiting the factors responsible for muscle and weight loss. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical company, announced favorable results from its Phase 2 study of Ponsegromab, a monoclonal antibody specifically targeting GDF-15, in patients afflicted with cancer cachexia. The study showcased a significant increase in body weight and improvements in muscle mass, appetite, and physical activity, with the 400 mg dose yielding the most robust outcomes. Based on these promising findings, Pfizer plans to begin registration-enabling studies in 2025 to further explore Ponsegromab’s potential in treating cancer cachexia.

Which Major Players Dominate The Cancer Cachexia Market?

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Read the full cancer cachexia market report here:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Which Region Currently Holds The Largest Share Of The Cancer Cachexia Market?

North America was the largest region in the cancer cachexia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Cachexia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

Browse Through More Reports Similar to the Global Cancer Cachexia Market 2026, By The Business Research Company

Skin Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Breast Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795